SOUTH SAN FRANCISCO, California, April 21, 2022 (GLOBE NEWSWIRE) – UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotech company developing therapies to slow, stop or reverse the diseases of aging, announced today that clinical data resulting from the Phase 1 study of its lead senolytic candidate, UBX1325, in patients with diabetic macular edema and macular degeneration age-related wetness will be presented at the 2022 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), which will be held from 1 to 4 May 2022. Przemyslaw (Mike) Sapieha, Ph.D., Chief Scientific Advisor for UNITY, he will also attend a speaking symposium to discuss the potential correlation between cellular senescence and eye disease, along with other scientific leaders in space. The details of the presentations are as follows:
Title: Cell senescence and immune response in eye health and disease
Appointment: Sunday 1 May 8: 00-10: 00 MT
Speakers: James L. Kirkland, Cintia S. De Paiva, Rajendra Apte, Dorota Skowronska-Krawczyk, Mike Sapieha and Raj Maturi
Title: UBX1325, a new senolytic treatment for patients with advanced DME or wet AMD: results at 24 weeks of a phase 1 study
Session: Presentation of the paper – AMD and retinal physiology
Appointment: Wednesday 4 May at 3:51 pm to 4:08 pm MT
Announcer: Robert Bhisitkul, MD, Ph.D., professor of ophthalmology and director of the Retina Fellowship at the University of California, San Francisco
Full presentations will be available virtually to ARVO attendees starting May 1, 2022 at 7:00 am ET. A recording of the symposium presentation and speeches will be available on the ARVO website on 11 May 2022.
UBX1325 is an investigational compound under study for age-related eye diseases, including diabetic macular edema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) that do not it is approved for any use in any country. UBX1325 is a potent small molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis-regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. In a Phase 1 clinical study in advanced vascular disease of the eye, UBX1325 showed a favorable safety profile and sustained improvements in visual acuity for 24 weeks after a single dose. In preclinical studies, UNITY demonstrated that targeting Bcl-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. UNITY’s goal with UBX1325 is to transformatively improve real-world outcomes for patients with DME, AMD and DR.
UNITY is developing a new class of therapies to slow, stop or reverse the diseases of aging. UNITY’s current goal is to create drugs to selectively eliminate or modulate senescent cells and thereby provide transformative benefits in age-related ophthalmological and neurological diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.
This press release contains forward-looking statements, including statements regarding UNITY’s understanding of cellular senescence and the role it plays in the diseases of aging, the potential for UNITY to develop therapies to slow, stop or reverse the diseases of aging, including for use ophthalmic and neurological diseases, our expectations regarding the potential benefits, activity, efficacy and safety of UBX1325, the potential for UNITY to successfully initiate and complete clinical trials of UBX1325 for DME, AMD and other ophthalmological diseases, expected timeline for results of our studies of UBX1325, the anticipated start, progression and termination times of our studies, including those of UBX1325, and UNITY’s expectations regarding the sufficiency of its cash track. These statements involve known and unknown risks, uncertainties and other material factors that could cause our actual results, business levels, performance or results to differ materially from the information expressed or implied in these forward-looking statements, including the risk that the global pandemic COVID-19 may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or discontinuing patient enrollment in clinical trials, risks related to uncertainties inherent in the drug development process, and risks related to UNITY’s understanding of the biology of senescence. We may not actually realize the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements contained in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will change our views. However, while we may decide to update these forward-looking statements in the future, we have no intention of doing so except to the extent required by applicable law. Therefore, you should not rely on these forward-looking statements as they represent our views at any date after the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to UNITY’s business in general, see UNITY’s latest annual report on Form 10 – K for the year ending December 31, 2021, filed with the Securities and Exchange Commission on March 15, 2022, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.
Contact with the media
Contact with investors
LifeSci Advisors, LLC